Generic Coreg CR Availability

See also: Generic Coreg

Coreg CR is a brand name of carvedilol, approved by the FDA in the following formulation(s):

COREG CR (carvedilol phosphate - capsule, extended release;oral)

  • Manufacturer: SB PHARMCO
    Approval date: October 20, 2006
    Strength(s): 10MG, 20MG, 40MG [RLD], 80MG

Has a generic version of Coreg CR been approved?

No. There is currently no therapeutically equivalent version of Coreg CR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Medicinal and/or nutritional microcapsules for oral administration
    Patent 6,022,562
    Issued: February 8, 2000
    Inventor(s): Autant; Pierre & Selles; Jean-Philippe & Soula; Gerard
    Assignee(s): Flamel Technologies
    The present invention relates to microcapsules for the oral administration of medicinal and/or nutritional active principles (AP), which are smaller than or equal to 1000 .mu.m in size. These microcapsules consist of particles which are coated with a coating material consisting of a mixture of a film-forming polymer derivative, a hydrophobic plasticizer, a functional agent and a nitrogen-containing polymer. These microcapsules are also characterized by their ability to remain in the small intestine for a long time (at least 5 hours) and to allow, during the residence, release and absorption of the AP. The invention also relates to a process for the production of the said microcapsules.
    Patent expiration dates:
    • October 17, 2015
      ✓ 
      Drug product
      ✓ 
      Sponsor has requested patent be delisted
    • April 17, 2016
      ✓ 
      Pediatric exclusivity
  • Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
    Patent 7,268,156
    Issued: September 11, 2007
    Inventor(s): Brook; Christopher S. & Chen; Wei & Spoors; Paul G.
    Assignee(s): SB Pharmco Puerto Rico Inc.
    The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
    Patent expiration dates:
    • June 27, 2023
      ✓ 
      Patent use: TREATMENT OF CONGESTIVE HEART FAILURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 27, 2023
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 27, 2023
      ✓ 
      Pediatric exclusivity
  • Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
    Patent 8,101,209
    Issued: January 24, 2012
    Inventor(s): Legrand; Valérie & Castan; Catherine & Meyrueix; Rémi & Soula; Gérard
    Assignee(s): Flamel Technologies
    The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 μm) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5. These microcapsules have a dissolution behavior in vitro such that, at a constant pH of 1.4, a latency phase of between 1 and 5 hours is observed, followed by a release of the AP, and such that the change from pH 1.4 to pH 6.8 results in a release of the AP without a latency period in vitro.
    Patent expiration dates:
    • September 11, 2025
      ✓ 
      Drug product
    • March 11, 2026
      ✓ 
      Pediatric exclusivity
  • Method of treatment for decreasing mortality resulting from congestive heart failure
    Patent RE40000
    Issued: January 8, 2008
    Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil Howard & Sponer; Gisbert & Strein; Klaus
    Assignee(s): SB Pharmco Puerto Rico Inc.
    A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.
    Patent expiration dates:
    • June 7, 2015
      ✓ 
      Patent use: DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
    • December 7, 2015
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)